司库奇尤单抗剂量递增对中轴型脊柱关节炎MRI炎症与结构损伤的影响:TRACE达标治疗研究
TRACE研究纳入90例生物制剂初治的活动性中轴型脊柱关节炎患者,司库奇尤单抗150 mg治疗16周后,ASDAS缓解者继续原剂量,未缓解者增至300 mg/月。16周时35%达ASDAS缓解,24周时49%缓解,其中22%为剂量递增后缓解;剂量递增对MRI炎症改善无统计学显著效应,但前4周即见显著MRI炎症下降和结构重塑。
要点
- 16周ASDAS未缓解者剂量递增至300 mg/月后,22%在24周达到ASDAS缓解
- 剂量递增对MRI炎症改善的主要终点无统计学显著效应(p=0.53)
- 司库奇尤单抗治疗前4周即出现显著MRI炎症下降和骶髂关节结构重塑
核心结论
- 司库奇尤单抗剂量递增对降低MRI检测的炎症无统计学显著效应,仅在部分选定亚组中观察到效果。
- 16周未缓解者剂量递增后,22%在24周达到ASDAS缓解。
- 治疗前4周即可观察到显著的MRI炎症下降和结构重塑。
研究设计与样本
- TRACE为多中心研究,纳入90例生物制剂初治的活动性中轴型脊柱关节炎患者。
- 司库奇尤单抗150 mg起始治疗16周后,ASDAS缓解者(<1.3)继续原剂量,未缓解者增至300 mg/月。
- 基线、第4、16、24周行骶髂关节和脊柱MRI,采用SPARCC和Canada-Denmark评分集中判读。
- 主要终点为第16-24周总MRI炎症改善≥2,比较16周缓解者与未缓解者。
主要发现
- 90例患者中68%为男性,平均年龄35.4岁。
- 第16周30例(35%)达到ASDAS缓解;第24周36例(49%)达到ASDAS缓解。
- 第24周ASDAS缓解者中10例(22%)为16周未缓解者,即剂量递增后缓解者。
- 第4周即观察到总MRI炎症(SPARCC脊柱+骶髂关节)显著下降(-14.7),并见骶髂关节侵蚀减少、脂肪增加和回填等结构重塑。
- 主要终点在16周缓解者中发生14例(52%),在16周未缓解者中发生19例(41%),p=0.53。
关键数值与推荐
- ASDAS缓解定义为<1.3。
- 主要终点为第16-24周总MRI炎症改善≥2。
- 第16周缓解者继续司库奇尤单抗150 mg,未缓解者增至300 mg/月。
临床怎么用
- 对司库奇尤单抗150 mg治疗16周未达ASDAS缓解的中轴型脊柱关节炎患者,可考虑剂量递增至300 mg/月,部分患者可获ASDAS缓解。
- 司库奇尤单抗治疗早期(4周内)即可评估MRI炎症和结构变化。
局限性
- 剂量递增对MRI炎症改善的主要终点无统计学显著效应,仅部分选定亚组显示数值差异。
- 原文未报告样本量计算、盲法、随机化等设计细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Evidence of treat-to-target strategies including secukinumab dose escalation in patients with axial spondyloarthritis (axSpA) remains limited. We investigated the effect of a treat-to-target approach aiming for Axial Spondyloarthritis Disease Activity Score (ASDAS) remission, assessed by clinical and MRI outcomes over 24 weeks. METHODS: TRACE was a multicentre study including biologic-naïve patients with active axSpA. Sixteen weeks after secukinumab 150 mg initiation, patients in ASDAS remission (<1.3)(week 16 remitters) continued the same dose, while non-remitters (week 16 non-remitters) escalated to 300 mg/month. Sacroiliac joint (SIJ) and spine MRIs were performed at baseline, weeks 4, 16 and 24, and centrally scored using Spondyloarthritis Research Consortium of Canada (SPARCC) and Canada-Denmark scores for inflammation and structural lesions. The primary end point was total MRI-inflammation improvement ≥2 (weeks 16-24) comparing week 16 remitters and week 16 non-remitters. RESULTS: Of 90 patients, 68% were male, mean age was 35.4 years. At week 16, 30 (35%) patients achieved ASDAS remission. At week 24, 36 (49%) patients were in ASDAS remission, including 10 (22%) week 16 non-remitters, who responded after dose escalation (dose-escalation responders).Already at week 4, marked reductions in total MRI inflammation (SPARCC spine+SIJ) (-14.7), and structural lesion remodelling (reduced SIJ erosion; increased SIJ fat and backfill), were observed. These changes continued through week 16, with only minor improvements thereafter.The primary end point occurred in 14 (52%) of week 16 remitters versus 19 (41%) of week 16 non-remitters (p=0.53). Dose-escalation responders had a numerically larger mean total MRI inflammation reduction (-6.1) than dose-escalation non-responders (-2.2). CONCLUSION: No statistically significant effect of secukinumab dose escalation on reducing MRI-detected inflammation was observed, except in a selected subgroup of patients. However, 22% achieved ASDAS remission after dose escalation. Notably, substantial MRI-detected inflammation reduction and structural remodelling occurred within the first 4 weeks. TRIAL REGISTRATION NUMBER: NCT03639740.
引用
- Vladimirova N, Østergaard M, Seven S, et al. Effect of secukinumab dose escalation on MRI-detected inflammation and structural damage in axial spondyloarthritis: a clinical, investigator-initiated, treat-to-target study (TRACE). RMD Open. 2026. PMID: 41963078. doi:10.1136/rmdopen-2026-006774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。